Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021:2286:213-225.
doi: 10.1007/7651_2020_282.

GMP-Compliant Production of Human Placenta-Derived Mesenchymal Stem Cells

Hamid Reza Aghayan  1 , Moloud Payab  2 , Fereshteh Mohamadi-Jahani  3 , Seyed Sajjad Aghayan  4 , Bagher Larijani  5 , Babak Arjmand  6   7
Affiliations

GMP-Compliant Production of Human Placenta-Derived Mesenchymal Stem Cells

Hamid Reza Aghayan et al. Methods Mol Biol. 2021.

Abstract

Mesenchymal stem cells are one of the most attractive sources for stem cell research and therapy. Their safety and efficacy have been demonstrated in many clinical trials. Because of their low immunogenicity and immunomodulatory properties, allogenic MSCs have been transplanted in different clinical studies. MSCs could be in different adult- and fetal-derived tissues including pregnancy products. Placenta-derived mesenchymal stem cells (PLMSCs) that can be harvested without using any invasive procedures from a discarding tissue are one of the important types of mesenchymal stem cells for therapeutic applications. Stem cell manufacturing for therapeutic applications should be in compliance with the basic principles of good manufacturing practice (GMP). Herein, the current chapter is to describe GMP-compliant production of human PLMSCs, which are suitable for clinical applications.

Keywords: Cell culture; Cell therapy; Clinical application; GMP; Mesenchymal stem cells; Placenta.

PubMed Disclaimer

References

    1. Ayala-Cuellar AP, Kang J-H, Jeung E-B et al (2019) Roles of mesenchymal stem cells in tissue regeneration and immunomodulation. Biomol Ther (Seoul) 27(1):25–33 - DOI
    1. Goodarzi P, Alavi-Moghadam S, Payab M et al (2019) Metabolomics analysis of mesenchymal stem cells. Int J Mol Cell Med 8(Suppl 1):30–40
    1. Soleimani M, Aghayan HR, Goodarzi P et al (2016) Stem cell therapy–approach for multiple sclerosis treatment. Arch Neurosci 3(1): e21564
    1. Arjmand B, Tirdad R, Saki Malehi A et al (2018) Stem cell therapy for multiple sclerosis. Cochrane Database Syst Rev 2018(6):CD013049 - PMC
    1. Goodarzi P, Aghayan HR, Larijani B et al (2015) Stem cell-based approach for the treatment of Parkinson’s disease. Med J Islam Repub Iran 29:168 - PubMed - PMC

MeSH terms

LinkOut - more resources